Pharmaceutical giants are actively lobbying the Trump administration and European Union officials to exclude medical goods from escalating trade disputes. They fear significant price increases and restricted patient access to essential medications. The industry’s concerns centre on the potential impact of tariffs on top-selling drugs like Novo Nordisk’s Wegovy for weight loss and Merck’s cancer immunotherapy Keytruda. In discussions with…